Wells Fargo raised the firm’s price target on Neurocrine to $127 from $110 and keeps an Equal Weight rating on the shares. The firm’s CAH survey suggests strong physician expectations for crinecerfont uptake suggesting a $1B-plus opportunity. This is a 2025-plus story though, which combined with recent stock move reduces urgency to own the name, Wells argues. Finally, the firm sees upward pressure on expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine initiated with bullish view at Deutsche Bank, here’s why
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
- Neurocrine receives FDA Breakthrough Therapy designation for crinecerfont
- Neurocrine price target raised to $139 from $134 at JPMorgan
- Neurocrine announces settlement of INGREZZA ANDA litigation